Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the use of autologous bone marrow stem cells mobilization using
1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an
effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium
(AE) and Recurrent Implantation Failure (RIF).